The average one-year price target for Fulcrum Therapeutics (NASDAQGM:FULC) has been revised to $7.75 / share. This is an increase of 11.22% from the prior estimate of $6.97 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not c
The average one-year price target for PLAYSTUDIOS (NASDAQCM:MYPS) (DB:7E3) has been revised to $5.10 / share. This is an increase of 900.00% from the prior estimate of $0.51 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not
The average one-year price target for NextNRG (NASDAQCM:NXXT) has been revised to $12.75 / share. This is an increase of 900.00% from the prior estimate of $1.28 dated September 11, 2026. These figures represent aggregate analyst targets and do not constitute a recommendation by
The average one-year price target for Azitra (NYSEAM:AZTR) has been revised to $0.68 / share on October 2, 2026, a decrease of 13.55% from the prior estimate of $0.79 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constit
The S&P 500 Index ($SPX ) (SPY ) closed up by +0.19% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.31%. December E-mini S&P futures (ESZ26 ) rose +0.20%, and December E-mini...
The average one-year price target for HeartBeam (NASDAQCM:BEAT) has been revised to $3.57 / share. This is an increase of 10.53% from the prior estimate of $3.23 dated September 11, 2026. These figures represent aggregate analyst targets compiled as of September 29, 2026, and do
On October 2, 2026, Piper Sandler upgraded their outlook for Alerus Financial (NASDAQCM:ALRS) (DB:5QD) from Neutral to Overweight. This rating action follows a prior action by the same firm on July 31, 2026, when Piper Sandler maintained its Neutral rating on the stock.Alerus Fin
The average one-year price target for AEON Biopharma (NYSEAM:AEON) has been revised to $1.81 / share, up 16.39% from the prior estimate of $1.56 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation o
Corn futures were fighting to stay above $5 for much of the session despite hitting a low of $4.95 in the December contract. Bulls battled back to close with contracts steady to 1 ½ cents higher. The CmdtyView national average Cash Corn price was up 3 1/4 cents at $4.61...
The average one-year price target for FMC (NYSE:FMC) (BMV:FMC1) has been revised to $13.75 / share, down 26.18% from the prior estimate of $18.63 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation
The average one-year price target for VolitionRx (NYSEAM:VNRX) has been revised to $13.89 / share. This is a decrease of 17.44% from the prior estimate of $16.83 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute
The average one-year price target for T3 Defense (NASDAQGM:DFNS) (DB:N860) has been revised to $66.30 / share. This is an increase of 116.67% from the prior estimate of $30.60 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel, rather t
The average one-year price target for AGNC Investment - Preferred Stock (NASDAQGS:AGNCO) has been revised to $31.50 / share. This is an increase of 10.30% from the prior estimate of $28.56 dated September 13, 2026. These figures represent aggregate analyst targe
The average one-year price target for Immix Biopharma (NASDAQCM:IMMX) has been revised to $25.04 / share. This is an increase of 10.16% from the prior estimate of $22.73 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not cons
The average one-year price target for Innate Pharma S.A. - Depositary Receipt (NASDAQGS:IPHA) (MUN:IDDA) has been revised to $8.22 / share. This is an increase of 27.91% from the prior estimate of $6.43 dated September 13, 2026. These figures represent aggregate analyst targets c
The average one-year price target for Karat Packaging (NASDAQGS:KRT) (MUN:0WJ) has been revised to $47.43 / share. This is an increase of 12.05% from the prior estimate of $42.33 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do
The S&P 500 Index ($SPX ) (SPY ) closed up by +0.19% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.31%. December E-mini S&P futures (ESZ26 ) rose +0.20%, and December E-mini...
The average one-year price target for Cable One (NYSE:CABO) (DB:XC1) has been revised to $62.22 / share. This is a decrease of 43.78% from the prior estimate of $110.67 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not const
The average one-year price target for NeuroSense Therapeutics (NASDAQCM:NRSN) (DB:H1Z) has been revised to $112.71 / share. This is an increase of 1,507.27% from the prior estimate of $7.01 dated September 11, 2026. These figures represent aggregate analyst targets compiled from